A Pilot Randomized Controlled Trial of Docosahexaenoic Acid for the Treatment of Sport-Related Concussion in Adolescents

Clin Pediatr (Phila). 2022 Nov;61(11):785-794. doi: 10.1177/00099228221101726. Epub 2022 Jun 19.

Abstract

The objective was to examine the use of docosahexaenoic acid (DHA) for the treatment of sport-related concussion (SRC) in adolescent athletes. We hypothesize that participants who intake 2 g of DHA daily will not experience differences in recovery compared with participants who take a placebo. This double-blind, randomized controlled pilot trial was performed in a tertiary pediatric sports medicine clinic from 2013 to 2017 in adolescents (14-18 years) presenting with diagnosed SRC within 4 days of injury. Forty participants were randomized into DHA or PLACEBO group and were instructed to take 2 capsules twice daily for 12 weeks. Participants in the DHA group were symptom-free earlier than the PLACEBO group (11.0 vs 16.0 days, P = .08) and were cleared to begin the Return to Sport progression (14.0 vs 19.5 days, P = .12) sooner. The use of 2 g/day of DHA was well-tolerated and did not significantly affect recovery times in adolescent athletes following SRC.Clinical Trial Registration: ClincalTrials.gov, NCT01903525.

Keywords: DHA; adolescent; recovery; sport-related concussion; treatment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Athletes
  • Athletic Injuries* / drug therapy
  • Brain Concussion* / diagnosis
  • Brain Concussion* / drug therapy
  • Child
  • Docosahexaenoic Acids / therapeutic use
  • Humans
  • Pilot Projects
  • Sports Medicine*

Substances

  • Docosahexaenoic Acids

Associated data

  • ClinicalTrials.gov/NCT01903525